A5033947419- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Renal Diseases and Glomerulopathies
- Monoclonal and Polyclonal Antibodies Research
- Atherosclerosis and Cardiovascular Diseases
- Liver Diseases and Immunity
- Autoimmune and Inflammatory Disorders Research
- T-cell and B-cell Immunology
- Peripheral Neuropathies and Disorders
- Systemic Sclerosis and Related Diseases
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Vasculitis and related conditions
- Cytokine Signaling Pathways and Interactions
- Hepatitis C virus research
- Multiple Sclerosis Research Studies
- Adrenal Hormones and Disorders
- Reproductive System and Pregnancy
- Inflammatory Myopathies and Dermatomyositis
- COVID-19 Clinical Research Studies
- Spondyloarthritis Studies and Treatments
- SARS-CoV-2 and COVID-19 Research
- Bone health and treatments
- Pharmacological Effects of Natural Compounds
- Bone health and osteoporosis research
Tuen Mun Hospital
2016-2025
University of Hong Kong
2000-2022
Queen Mary Hospital
1997-2022
Prince of Wales Hospital
2022
Queen Elizabeth Hospital
2022
Chinese University of Hong Kong
2022
Kwong Wah Hospital
2022
University of Cambridge
2016
Addenbrooke's Hospital
2016
Pok Oi Hospital
2012
Systemic lupus erythematosus is a complex and potentially fatal autoimmune disease, characterized by autoantibody production multi-organ damage. By genome-wide association study (320 patients 1,500 controls) subsequent replication altogether involving total of 3,300 Asian SLE from Hong Kong, Mainland China, Thailand, as well 4,200 ethnically geographically matched controls, genetic variants in ETS1 WDFY4 were found to be associated with (ETS1: rs1128334, P = 2.33×10−11, OR 1.29; WDFY4:...
Objectives To update the EULAR recommendations for management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed questions systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation statements after a series meetings. A predefined voting process was applied to each overarching principle recommendation. Levels evidence strengths recommendation were assigned, participants finally provided...
Objective To study the effect of renal disease on standardized mortality ratio (SMR) and life expectancy patients with systemic lupus erythematosus (SLE). Methods Patients whose diagnosis met ≥4 American College Rheumatology criteria for SLE were longitudinally followed up from 1995 to 2011. The cumulative survival rate, SMR, calculated, involvement, histologic class nephritis, damage, end‐stage (ESRD) these parameters was evaluated. Results Of 694 studied, 368 (53%) had disease,...
The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. conference focused the 2012 KDIGO guideline with aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, particular, therapy since guideline's publication. It was consensus group that most recommendations, particular those dealing therapy, will need to be revisited by guideline-updating Work Group. This report covers...
<h3>Objective</h3> To compare the efficacy of tacrolimus (TAC) and mycophenolate mofetil (MMF) for initial therapy lupus nephritis (LN). <h3>Study design</h3> This is an open randomised controlled parallel group study. <h3>Methods</h3> Adult patients with biopsy-confirmed active LN (class III/IV/V) were to receive prednisolone (0.6 mg/kg/day 6 weeks tapered) in combination either TAC (0.06–0.1 mg/kg/day) or MMF (2–3 g/day) months. Good responders shifted azathioprine maintenance. The primary...
Systemic lupus erythematosus (SLE), a worldwide autoimmune disease with high heritability, shows differences in prevalence, severity and age of onset among different ancestral groups. Previous genetic studies have focused more on European populations, which appear to be the least affected. Consequently, variations that underlie commonalities, treatment options SLE groups not been well elucidated. To address this, we undertake genome-wide association study, increasing sample size Chinese...
In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss 2012 KDIGO glomerulonephritis guideline context new developments and insights that had occurred over years since its publication. During this Controversies Conference on Glomerular Diseases, group examined data disease pathogenesis, biomarkers, treatments identify areas consensus controversy. This report summarizes discussions...
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication systemic erythematosus (SLE). CD6 and its ligand, activated leukocyte cell adhesion molecule (ALCAM), involved in activation trafficking. Previously, we showed that soluble ALCAM is increased urine (uALCAM) patients with LN, suggesting this pathway contributes disease. To investigate, uALCAM was examined 1038 SLE LN from 5 ethnically diverse cohorts; expression assessed kidney cells; disease contribution...
Abstract Objective To compare the incidence and risk factors for thromboembolic events in systemic lupus erythematosus (SLE) patients of different ethnic backgrounds. Methods SLE who were newly diagnosed or referred within 6 months diagnosis between 1996 2002 prospectively followed up occurrence events. Cumulative hazard thromboembolism evaluated compared among origins. Results We studied 625 fulfilled American College Rheumatology criteria (89% women): 258 Chinese, 140 African Americans,...
To evaluate the immunogenicity and safety of GARDASIL, a quadrivalent human papillomavirus (HPV) vaccine, in patients with systemic lupus erythematosus (SLE).Women SLE aged 18-35 years who had stable disease were recruited to receive GARDASIL vaccination an equal number age-matched healthy women also vaccinated. Seroconversion rates antibodies HPV serotypes 6, 11, 16 18 at months 7 12 adverse events (AEs) compared between controls. The rate flares participants was matched controls.50 50...
To study the survival rate and prognostic indicators of systemic lupus erythematosus (SLE) in a southern Chinese population.One hundred eighty-six patients with SLE diagnosed between 1992 1999 were prospectively followed. Clinical features at presentation, subsequent evolving features, autoantibody profile, damage scores mortality data obtained. Prognostic factors for studied by statistical analysis.One sixty-three female 23 male studied. The to ratio was 7.1 1 mean age presentation 33.6 yr...
To study the incidence, predictors, and outcome of renal flares after successful cyclophosphamide (CYC) treatment for diffuse proliferative glomerulonephritis (DPGN) in patients with systemic lupus erythematosus (SLE).Between 1988 2001, biopsy-proven SLE DPGN who were treated initially prednisone CYC studied. Those responded to followed up occurrence flares. The cumulative risk, evaluated.We studied 189 (167 women; 22 men) DPGN. All (49% orally; 51% by intravenous pulse). At last dose CYC,...
To evaluate the prevalence of metabolic syndrome in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic (PsA).Consecutive RA, AS, or PsA who attended our outpatient clinics between July November 2009 were recruited for a study atherosclerotic risk factors syndrome, defined according to joint statements using Asian criteria central obesity.Nine hundred thirty studied (699 122 109 PsA; 70% women, mean±SD age 51.1±12.7 years). The disease duration was 5.3±5.4,...
We conducted the current study to determine clinical determinants of survival and rates in an unselected cohort Chinese patients with new-onset systemic lupus erythematosus (SLE), including all age-groups. Patients were those newly diagnosed as having SLE or referred within 6 months diagnosis departments medicine, geriatrics, pediatrics at Tuen Mun Hospital, Hong Kong, between 1991 2003. under care specialists included for analysis. obtained demographic data, presenting cumulative features,...
To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine potential relationship trough drug concentration, efficacy, patient-reported outcomes.This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult RA continuously for 6-24 months ETN, ADL, IFX. ADA concentrations were measured by independent assays ≤2 days before next...
To study the relationship between serum hydroxychloroquine (HCQ) concentrations and flares of systemic lupus erythematosus (SLE) in a longitudinal cohort patients.Patients who fulfilled ≥4 American College Rheumatology classification criteria for SLE had been treated with HCQ >6 months were studied. Blood was assayed levels by tandem mass spectrometry. Patients serially assessed disease activity, using Safety Estrogens Lupus Erythematosus National Assessment (SELENA) version Systemic Disease...
Abstract Emerging urinary biomarkers continue to show promise in evaluating lupus nephritis (LN). Here, we screen urine from active LN patients for 1129 proteins using an aptamer-based platform, followed by ELISA validation two independent cohorts comprised of 127 inactive lupus, 107 LN, 67 non-renal and 74 healthy controls, three different ethnicities. Urine that best distinguish disease are ALCAM, PF-4, properdin, VCAM-1 among African-Americans, sE-selectin, VCAM-1, BFL-1 Hemopexin...